Drug Profile
Oxeglitazar
Alternative Names: EMD 336340; LM 4156Latest Information Update: 07 Apr 2009
Price :
$50
*
At a glance
- Originator Merck Sante
- Class Antihyperglycaemics; Antihyperlipidaemics; Benzoxepins; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gout; Metabolic syndrome; Type 2 diabetes mellitus
Most Recent Events
- 13 Dec 2005 Phase-I clinical trials in Gout in France (PO)
- 13 Dec 2005 Data presented at the 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2005) have been added to the Rheumatic disease pharmacodynamics section
- 29 Aug 2003 Data presented at the 18th Congress of the International Diabetes Federation (IDF-2003) have been added to the Diabetes pharmacodynamics , pharmacokinetics and drug interactions sections